Comparative activity of Choristoneura fumiferana nucleopolyhedrovirus propagated in different hosts

The biological activity of the Ireland strain of Choristoneura fumiferana (Clem) nucleopolyhedrovirus (CfMNPV) propagated in different hosts was determined to provide the basis upon which genetically modified CfMNPV, or other naturally occurring isolates, should be compared. Occlusion bodies (OB) derived from CF-203 cells were significantly larger and more pathogenic than those propagated in vivo when tested against the fifth larval instar of C fumiferana (Clem) and C occidentalis Freeman. The dose-responses (LD50 and LD95, expressed as occlusion bodies per larva) of C fumiferana larvae to in vitro-propagated OBs were 274 and 5785, respectively. The values of LD50 and LD95 to C occidentalis larvae were 19 and 118, respectively. There were no significant differences in pathogenicity or size when OBs propagated in C fumiferana larvae were tested against either insect species, nor were there significant differences for OBs propagated in C occidentalis larvae. The LD50 and LD95 of in vivo-produced OBs to C fumiferana were 925 and 61988, respectively. The LD50 and LD95 to C occidentalis were 50 and 453, respectively. OBs propagated in vitro had a mean volume of 13.13 microm3, whereas those propagated in vivo ranged from 0.84 to 1.41 microm3. The median survival time-responses (ST50) of fifth-instar C fumiferana or C occidentalis larvae to OBs propagated in vivo were not significantly different from those propagated in vitro at the dosage levels tested. Values of ST50 of C fumiferana larvae to in vitro- and in vivo-produced OBs at dosages causing less than 50% mortality rangedfrom 9.6 to 9.8 days post-inoculation (dpi), whereas a LD95 dose resulted in ST50 values ranging from 7.3 to 7.7 days. ST50 values of C occidentalis larvae at dosages causing less than 50% mortality ranged from 9.8 to 10.2 dpi, whereas a LD95 dose resulted in ST50 values ranging from 9.5 to 9.8 dpi. The median feeding cessation time-response (FT50) of fifth-instar C fumiferana larvae to OBs propagated in vitro (5.7 days) was not significantly different from the FT50 of those propagated in vivo in either insect species (5.3 and 5.7 days) at the dosage level tested (LD95). No significant differences in FT50 values were observed between OBs propagated in either larval host. The FT50 of C occidentalis larvae to OBs propagated in vitro (7.7 days) was not significantly different from that to those propagated in vivo in C occidentalis larvae (7.6days), but somewhat different (7.2 days) from that to those propagated in C fumiferana larvae. Results indicate that CfMNPV can be propagated in vivo in either C fumiferana or C occidentalis larvae (or sequentially through both) without alteration in infectivity, although the use of the CF-203 cell line yields the most biologically active OBs.     

In vitro effect of recombinant human tumor necrosis factor-alpha on canine neutrophil apoptosis

Neutrophils (polymorphonuclear leukocytes: PMNs) are essential for the host defense against various infections and are often injurious to the host, causing inflammatory diseases where tumor necrosis factor-alpha (TNF-alpha) is suggested to play an important role. Since an effect of TNF-alpha on canine PMN apoptosis has not been studied, canine PMNs were stimulated with recombinant human (rh)TNF-alpha in the present study to investigate the effect of TNF-alpha on canine PMN apoptosis. PMN apoptosis and function to produce ROS were assessed by flow cytometry. Delayed apoptosis was observed in the PMNs treated with rhTNF-alpha at 100 ng/ml, accompanied by retention of capability to produce ROS. However, PMN apoptosis was accelerated by rhTNF-alpha combined with cycloheximide. Therefore, it is indicated that TNF-alpha is able to activate anti- and pro-apoptotic pathways in PMNs and that the inhibition of PMN apoptosis by TNF-alpha requires protein synthesis in the PMNs.     

水稻功能叶相关性状的遗传分析

利用由小穗小粒型水稻Milyang 46和大穗大粒型FJCD建立的一个包含130个家系F10的重组自交系,测定福建省武夷山和莆田环境下籽粒灌浆期功能叶性状,并进行QTL定位及环境互作分析.结果表明,2种环境下共检测到35个加性QTL,位于1、2、5、6、7、11、12号染色体上,表型变异贡献率为0.66%-56.75%;检测到12个位点存在显著的加性×环境互作效应,位于1、2、6、11号染色体上,表型变异贡献率为1.45%-12.05%;莆田环境下,检测到7对加加上位性QTL位点,表型变异贡献率为0-15.64%.     

极具潜力的重组药用蛋白的毛状根表达系统研究

对植物表达系统产生重组药用蛋白进行了简单的介绍,重点论述了利用发根农杆菌诱导的毛状根培养系统表达重组药用蛋白的研究及应用情况。     

猪囊尾蚴重组抗原和基因工程疫苗的研究进展

猪囊尾蚴病（Cysticercosis）是由猪带绦虫的幼虫囊尾蚴寄生于人或猪等而引起的人畜共患寄生虫病,是公认的世界经济病之一。严重威胁着人体健康,并给畜牧业造成重大经济损失,猪囊尾蚴病的免疫防治势在必行。然而在猪囊尾蚴病疫苗研究中,疫苗抗原的选择和来源一直困扰着兽医工作者。该文就近年来猪囊尾蚴病诊断重组抗原和基因工程疫苗的分子生物学研究进展进行了综述。     

自身启动子控制的卡那霉素抗性基因在哺乳动物细胞中表达的检测

为了研究卡那霉素抗性(KanR)基因能否在哺乳动物细胞中表达以及用含相同抗性基因重组质粒防治奶牛乳腺炎的安全性,用PCR从重组质粒p215C3LYZ中扩增得KanR基因,将其克隆入原核表达载体pQE-31,用含卡那霉素(Kan)琼脂平板筛选得KanR重组菌,经IPTG诱导成功表达了预期大小的Kan抗性融合蛋白;用纯化的重组蛋白免疫小鼠,获得了Kan抗性蛋白抗血清,经Western blotting证明免疫血清特异性良好;分别用重组质粒pQE-Kan和p215C3LYZ转染COS-1细胞,在不含抗生素培养液中培养后分别收集细胞上清和细胞裂解物;将转染细胞上清分为添加和不加Kan组,接种Kan敏感菌DH5α大肠杆菌,培养物的OD600检测结果显示,添加组的指示菌生长被抑制,转染细胞上清中无Kan抗性蛋白表达;以Kan抗性蛋白免疫血清进行的Western blotting结果显示,转染细胞内无Kan抗性蛋白表达;将p215C3LYZ注射奶牛乳腺,用脱脂和浓缩奶样进行Western blotting检测,结果显示试验牛乳中也无Kan抗性蛋白表达。这些试验结果提示,来源于原核大肠杆菌的KanR基因启动子在动物细胞中无转录活性,乳腺注射含KanR基因的重组质粒不会表达对奶牛和人体有害的Kan抗性蛋白。     

口蹄疫病毒P1-2A和3C蛋白重组腺病毒的构建及其免疫原性研究

为研制口蹄疫病毒(FMDV)的新型重组腺病毒疫苗,本研究通过RT-PCR扩增FMDV GD株3C、P1、P1-2A、L-P1和L-2A基因,分别构建重组腺病毒穿梭质粒,并在含有腺病毒骨架质粒pAdEasy-1的BJ5183E.coli中同源重组获得腺病毒重组质粒pAd-3C、pAd-P1、pAd-P1-2A、pAd-L-P1、pAd-L-2A,经PacⅠ线性化后转染AD-293细胞,获得含有目的基因的重组腺病毒。将具有感染能力的复制缺陷型重组腺病毒rAd-3C分别与rAd-P1、rAd-P1-2A、rAd-L-P1、rAd-L-2A共感染Vero细胞,裂解细胞收集细胞上清液并进行小鼠免疫试验。经ELISA检测表明,重组腺病毒rAd-3C分别与rAd-P1-2A、rAd-L-2A共感染Vero细胞上清液能够诱导小鼠产生特异性体液免疫应答。     

共表达O型FMDV衣壳蛋白和绿色荧光蛋白重组腺病毒的构建

为构建表达O型口蹄疫病毒(FMDV)的P12A3C基因及GFP基因的重组腺病毒rAdV-P12aEGFP2a3C,本研究以FMDV的2A基因序列为Linker,将报告基因EGFP插入FMDV的P12A与3C之间。重组腺病毒感染HEK-293细胞后可以观察到绿色荧光,表明EGFP蛋白获得表达。应用FMDV的VP2单克隆抗体4B2对重组病毒感染细胞进行western blot检测,反应条带与FMDV衣壳蛋白VP0和VP3的分子量大小相符,表明FMDV的完整衣壳蛋白和3C蛋白酶也均获得表达,而且EGFP的插入并未影响P1蛋白的表达和3C蛋白酶对P1的正确切割。重组腺病毒的生长特性分析表明,EGFP的插入也未影响该重组腺病毒的增殖特性。上述研究结果显示,表达FMDV衣壳蛋白P12A3C的重组腺病毒可以作为载体,以2A蛋白作为Linker表达一个小分子蛋白,为改进以腺病毒为载体的口蹄疫基因工程疫苗提供了新思路。     

表达犬瘟热病毒H基因重组新城疫病毒的构建及其免疫原性研究

为研制安全、有效的新型犬瘟热疫苗,本研究利用新城疫病毒(NDV) LaSota弱毒疫苗株反向遗传操作系统,构建出表达犬瘟热病毒(CDV)弱毒疫苗株Rockborn-20/8血凝素(H)蛋白的重组病毒rLa-CDV-H,并对其生物学特性进行鉴定,评估其作为犬瘟热活载体疫苗的安全性和有效性.通过免疫荧光和western blot试验证明了CDV H蛋白的正确表达;重组病毒株保持了LaSota亲本株的低致病性和高滴度鸡胚生长特性;重组病毒rLa-CDV-H接种12周龄比格犬后,可以诱导显著的CDV中和抗体反应.本研究表明重组病毒rLa-CDV-H具有作为犬瘟热重组病毒活载体疫苗的潜力.     

重组猪干扰素α1冻干粉针剂在猪体内的药代动力学研究

为研究重组猪干扰素α1 (rPoIFN-α1)冻干粉针剂在猪体内的药代动力学特征,本研究将实验猪随机分为3组:分别静脉、肌肉和皮下注射rPoIFN-α1 1.0×107 IU,每组设立对照组,于注射后间隔不同时间采血,采用细胞病变抑制法测定其血清样品中rPoIFN-α1的效价.结果表明,肌肉注射组和皮下注射组药动学特征符合一室开放模型,呈一级动力学消除,血药峰时间(Tmax)分别为2.872±0.314 h和4.000±0.539 h,消除半衰期(T1/2)分别为6.236±0.551 h和6.644±0.751 h,血药峰浓度(Cmax)分别为3.980±2.875× 104 IU/L和1.080±0.986× 104 IU/L.静脉注射组符合二室开放模型,呈一级动力学消除,分布半衰期(T1/2α)为0.136±0.021 h,消除半衰期(T1/2β)为5.195±0.351 h,Cmax值为6.380±0.546× 104 IU/L.rPoIFN-α1静脉、肌肉和皮下注射组清除率分别为0.930±0.132 L/h、0.677±0.228 L/h和0.879±0.210 L/h.与静脉注射组相比,肌肉注射组的生物利用度为47.82％,皮下注射组的生物利用度为35.09％.本实验结果提示这3种rPoIFN-α1的注射方法在猪体内吸收、消除较快,具有线性动力学特征.rPoIFN-α1肌肉注射给药的生物利用度高于皮下注射组,消除半衰期比静脉注射组延长,可以作为替代静脉注射的一种方便和安全给药途径.